Involvement of cytokines in cachexia induced by T-cell leukaemia in the rat

European Cytokine Network

Volumn 8, Issue 1, 1997, Pages 45-49

  Roe, S Y ^a   Cooper, A L ^a   Morris, I D ^a   Hopkins, S J ^a   Rothwell, N J ^a  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

Author keywords

Cachexia; Cytokines; IL 6; Rat; T cell leukaemia

Indexed keywords

CYTOKINE; INTERLEUKIN 1; INTERLEUKIN 6; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD LEVEL; CACHEXIA; CONTROLLED STUDY; MALE; NONHUMAN; RAT; T CELL LEUKEMIA; WEIGHT REDUCTION;

ANIMALS; CACHEXIA; INTERLEUKIN-1; INTERLEUKIN-6; LEUKEMIA, T-CELL; MALE; RATS; TUMOR NECROSIS FACTOR-ALPHA;

ANIMALIA;

EID: 0030936946     PISSN: 11485493     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (38)

1. Strain A J. 1979. Cancer cachexia in man: a review. Invest. Cell Pathol. 2:181.
2. Langstein H N, Norton J A. 1991. Mechanisms of cancer cachexia. Haemat. Oncol. Clin. North Am. 5:103 .
3. Rothwell N J. 1990. Mechanisms of the pyrogenic actions of cytokines. Eur Cytokine Net. 1 :211 .
4. Fujimoto-Ouchi K, Tamura S, Mori K, Tanaka Y, Ishitsuka H. 1995. Establishment and characterization of cachexia-inducing and-non-inducing clones of murine colon 26 carcinoma. Int. J. Cancer. 61:522.
5. Krurzrock R, Redman J, Cabanillas F, Jones D, Rothberg J, Talpaz M. 1993. Serum interleukin 6 levels are elevated in lymphoma patients and correlate with survival in advanced Hodgkin's Disease and with B symptoms. Cancer Res. 53:2118.
6. Strassmann G, Fong M, Kenney J S, Jacob C O. 1992. Evidence for the involvement of interleukin 6 in experimental cancer cachexia. J. Clin. Invest. 89:1681.
7. Dibley M, Dorsch S, Roser B. 1975. T-cell leukaemia in the rat: The pathophysiology. Pathology 7:219.
8. Luheshi G N, Miller, A J, Brouwer S, Dascombe M J, Rothwell N J, Hopkins S J. 1995. Interleukin-1 receptor antagonist inhibits endotoxin fever and systemic interleukin-6 induction in the rat. Am. J. Physiology 270:E91.
9. Hopkins S J, Humphreys M. 1989. Simple, sensitive and specific bioassay of interleukin-1. J. Immunological. Meth. 120:271.
10. Hopkins S J, Humphreys M. 1990. Bioassay of interleukin-1 in serum and plasma following removal of inhibitory activity with polyethylene glycol. J. Immunol. Methods. 133:127.
11. Matthews N, Neale M L. 1986. Cytotoxicity assays for tumour necrosis factor and lympholoxin. In: Clemens M J, Morris A G, Gearing A J H. Eds Lymphokines and Interferons, : IRL press, 221.
12. Roe S Y, Cooper A L, Morris I D, Rothwell N J. 1996. Mechanisms of cachexia induced by T-cell leukaemia in the rat. Metabolism 45:645 .
13. Strassmann G, Masui Y, Chizzonile R, Fong M. 1993. Mechanisms of experimental cancer cachexia. A local involvement of IL-1 in colon-26 tumor. J. Immunol. 150:2341.
14. Gelin J, Andersson C, Lundholm K. 1991. Effects of indomethacin, cytokines and cyctosporin A on tumor growth and the subsequent development of cancer cachexia. Cancer Res. 51 :880.
15. Socher S H, Martinez D, Craig J B, Kuhn J G, Oliff A. 1988. Tumor necrosis factor not detectable in patients with clinical cancer cachexia. J. Natl. Cancer Inst. 80:595.
16. Moldawer L L, Gelin J, Schersten T, Lundholm K G. 1987. Circulating interleukin 1 and tumor necrosis factor during inflammation. Am. J. Physiol. 253:R922.
17. Waage A, Espevik T, Lamvik J. 1986. Detection of tumour necrosis factor-like cytotoxicily in serum from patients with septicaemia but not from untreated cancer patients. Scand. J. Immunol. 24:739.
18. Gelin J, Moldawer L L, Lonnroth C, Sherry B, Chizzonite R, Lun&olm K. 1991. Role of endogenous tumor necrosis factor a and interleukin 1 for experimental tumor growth and the development of cancer cachexia. Cancer Res 51:415.
19. Moldawer L, Drott C, Lundholm K. 1988. Monocytic production and plasma bioactivities of interleukin-1 and tumour necrosis factor in human cancer. Eur. J. Clin. Invest. 18:486.
20. Yoneda T, Alsina M A, Chavez J B, Bonewald L, Nishimura R, Mundy G R. 1991. Evidence that tumor necrosis factor plays a pathogenetic role in the paraneoplastic syndromes of cachexia, hypercalcemia, and leukocytosis in a human tumor in nude mice. J. Clin. Invest. 87:977.
21. Larrick J W. 1989. Native interleukin 1 inhibitors. Immunol. Today. 10:61.
22. Seckinger P, Isaaz S, Dayer J -M. 1989. Purification and biologic characterization of specific tumor necrosis tactor cc inhibitor. J. Biol. Chem. 264:11966.
23. Kriegler M, Perez C, DeFay K, Albert I, Lu S D. 1988. A novel form of TNF/cachectin is a cell surface cytotoxic transmembrane protein: ramifications for the complex physiology of TNF. Cell. 53:45
24. Lonnroth C, Moldawer L L, Gelin J, Kindblom L, Sherry B, Lundholm K. 1990. Tumor necrosis factor-α and inlerleukin-1α production in cachectic tumor-bearing mice. Int. J. Cancer. 46:889.
25. Sheppard B C, Venzon D, Fraker D L, Langstein H N, Jenson J C, Norton J A. 1990. Prolonged survival of tumor-bearing rats with repetitive low dose recombinant tumor necrosis factor. Cancer Res. 50:3928.
26. Helfgott D C, May L T, Sthoeger Z, Tanim I, Sehgal P B. 1987. Bacterial lipopolysaccharide (endotoxin) enhances expression and secretion of β2-interferon by human fibroblasts. J. Exp. Med. 616:1300.
27. Kohase M, May L T, Tamm I, Vilcek J, Sehgal P B. 1987. A cytokine network in human diploid fibroblasts: interaction of β-interferons, tumour necrosis factor, platlet-derived factor, and interleukin-1. Mol. Cell Biol. 7:273.
28. Heinrich P C, Castell J V, Andus T. 1990. Interleukin-6 and the acute phase response. Biochem. J. 265:621.
29. Hirano T, Akira S, Taga T, Kishimolo T. 1990. Biological and clinical aspects of interleukin-6. Immunol. Today. 11:443.
30. Klein B, Zhang X-G, Jourdan M, Boiron J-M, Portier M, Lu Z-Y, Wijdenes J, Brochier J, Bataille R. 1990. Interleukin-6 is the central tumor growth factor in vitro and in vivo in multiple myeloma. Eur. Cytokine Net. 1:193.
31. Kawano M, Hirano T, Matsuda T, Taga T, Horii Y, Iwato K, Asaoku H, Tang B, Tanabe O, Tanaka H, Kuramoto A, Kishimoto T. 1988. Autocrine generation and requirement of BSF-2/IL-6 for human multiple myelomas. Nature. 332:83.
32. Tsujinaka T, Fujita J, Ebisui C, Yano M, Kominami E, Suzuki K, Tanaka K, Katsume A, Ohsugi Y, Shiozaki H, Monden M. 1996. Interleukin 6 receptor antibody inhibits muscle atropy and modulates proleolytic systems in interleukin-6 transgenic mice. J. Clin. Invest. 97: 244.
33. Yoshizawa K, Okamoto T, Moriya K, Izawa A, Satoh Y, Naruto M, Ida N. 1994. Effects of natural human interleukin-6 on thrombopoiesis and tumor progression in tumor-bearing mice. Cancer. Lett. 79:83.
34. Beck J T, Hsu S-M, Wijdenes J, Bataille R, Klein B, Vesole D, Hayden K, Jagannath S, Barlogie B. 1994. Brief report: Alleviation of systemic manifestations of Castleman's disease by monoclonal anti-interleukin-6 antibody. N. Eng. J. Med. 602.
35. Emilie D, Wijdenes J, Gisselbrecht C, Jarousse B, Billaud E, Blay J-Y, Gabarre J, Gaillard J-P, Brochier J, Raphael M, Boue F, Galanaud P. 1994. Administration of anti-interleukin-6 monoclonal antibody to patients with acquired immunodeficiency syndrome and lymphoma: Effect on lymphoma growth and on B clinical symptoms. Blood 84:2472.
36. Roe S Y, Cooper A L, Morris I D, Rothwell N J. Involvement of prostaglandins in cachexia induced by T-cell leukaemia in the rat. Metabolism (in press).
37. Nabel G J, Grunfeld C. 1996. Calories lost- another mediator of cancer cachexia? Nat. Med. 2:397.
38. May L T, Neta R, Moldawer L L, Kenney J S, Patel K, Sehgal P B. 1993. Antibodies chaperone circulating IL-6. Paradoxical effects of anti-IL-6 "neutralising" antibodies in vivo. J. Immunol. 151:3225.